1085 related articles for article (PubMed ID: 26091634)
1. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
[TBL] [Abstract][Full Text] [Related]
2. Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A.
Valentin JP; Bass AS; Atrakchi A; Olejniczak K; Kannosuke F
J Pharmacol Toxicol Methods; 2005; 52(1):22-9. PubMed ID: 15961324
[TBL] [Abstract][Full Text] [Related]
3. Benchmarking safety pharmacology regulatory packages and best practice.
Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
[TBL] [Abstract][Full Text] [Related]
4. Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society.
Bass AS; Vargas HM; Valentin JP; Kinter LB; Hammond T; Wallis R; Siegl PK; Yamamoto K
J Pharmacol Toxicol Methods; 2011; 64(1):7-15. PubMed ID: 21689769
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2006; 54(2):94-8. PubMed ID: 16806993
[TBL] [Abstract][Full Text] [Related]
7. Origins, practices and future of safety pharmacology.
Bass A; Kinter L; Williams P
J Pharmacol Toxicol Methods; 2004; 49(3):145-51. PubMed ID: 15172010
[TBL] [Abstract][Full Text] [Related]
8. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
9. Exploratory drug safety: a discovery strategy to reduce attrition in development.
Bass AS; Cartwright ME; Mahon C; Morrison R; Snyder R; McNamara P; Bradley P; Zhou YY; Hunter J
J Pharmacol Toxicol Methods; 2009; 60(1):69-78. PubMed ID: 19422924
[TBL] [Abstract][Full Text] [Related]
10. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
Kuhlmann J
Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
[TBL] [Abstract][Full Text] [Related]
11. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis.
Cavero I; Crumb W
Expert Opin Drug Saf; 2005 May; 4(3):509-30. PubMed ID: 15934857
[TBL] [Abstract][Full Text] [Related]
12. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies.
Friedrichs GS; Patmore L; Bass A
J Pharmacol Toxicol Methods; 2005; 52(1):6-11. PubMed ID: 15975833
[TBL] [Abstract][Full Text] [Related]
13. The Diplomate in Safety Pharmacology (DSP) certification scheme.
Authier S; Curtis MJ; Soloviev M; Redfern WS; Kallman MJ; Hamlin RL; Leishman DJ; Valentin JP; Koerner JE; Vargas HM; Botchway A; Correll K; Pugsley MK
J Pharmacol Toxicol Methods; 2015; 75():1-4. PubMed ID: 25959882
[TBL] [Abstract][Full Text] [Related]
14. Methodological innovations expand the safety pharmacology horizon.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
[TBL] [Abstract][Full Text] [Related]
15. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
[TBL] [Abstract][Full Text] [Related]
16. Trends in safety pharmacology: posters presented at the annual meetings of the Safety Pharmacology Society 2001-2010.
Redfern WS; Valentin JP
J Pharmacol Toxicol Methods; 2011; 64(1):102-10. PubMed ID: 21635957
[TBL] [Abstract][Full Text] [Related]
17. Methods in safety pharmacology in focus.
Pugsley MK; Gallacher DJ; Towart R; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2008; 58(2):69-71. PubMed ID: 18707009
[TBL] [Abstract][Full Text] [Related]
18. Methodology used in safety pharmacology: appraisal of the state-of-the-art, the regulatory issues and new directions.
Pugsley MK
J Pharmacol Toxicol Methods; 2005; 52(1):1-5. PubMed ID: 15982903
[TBL] [Abstract][Full Text] [Related]
19. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
Pugsley MK; Curtis MJ; Hayes ES
Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
[TBL] [Abstract][Full Text] [Related]
20. Rethinking Giftedness and Gifted Education: A Proposed Direction Forward Based on Psychological Science.
Subotnik RF; Olszewski-Kubilius P; Worrell FC
Psychol Sci Public Interest; 2011 Jan; 12(1):3-54. PubMed ID: 26168418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
